{
  "meta": {
    "title": "17_Coagulation_Disorders",
    "url": "https://brainandscalpel.vercel.app/17-coagulation-disorders-bec81bfa.html",
    "scrapedAt": "2025-11-30T06:57:03.496Z"
  },
  "questions": [
    {
      "id": 83141,
      "choices": [
        {
          "id": 294087,
          "text": "Autosomal recessive"
        },
        {
          "id": 294088,
          "text": "Autosomal dominant"
        },
        {
          "id": 294089,
          "text": "X-linked recessive"
        },
        {
          "id": 294090,
          "text": "X-linked dominant"
        }
      ],
      "text": "Pattern of inheritance of Hemophilia :",
      "unique_key": "Q3967281",
      "question_audio": null,
      "question_video": null,
      "map_id": 34859867,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) X-linked recessive. Hemophilia is a bleeding disorder caused by mutations in genes responsible for producing clotting factors, most commonly factor VIII (Hemophilia A) or factor IX (Hemophilia B). These genes are located on the X chromosome. Since males have only one X chromosome (XY), a single defective gene on the X chromosome will result in the disease. Females, on the other hand, have two X chromosomes (XX), so a defective gene on one X chromosome is typically compensated by the normal gene on the other X chromosome. As a result, females are usually carriers and rarely show symptoms. Hemophilia exhibits a clear X-linked recessive inheritance pattern, where the condition predominantly affects males, and carrier females can pass the mutated gene to their offspring. A. Autosomal recessive This option is incorrect because autosomal recessive disorders are caused by mutations in genes located on non-sex chromosomes (autosomes). Both copies of the gene (one from each parent) must be mutated for the disease to manifest. Since hemophilia is caused by mutations in genes on the X chromosome, it does not follow this inheritance pattern. B. Autosomal dominant This option is incorrect because autosomal dominant disorders occur when a mutation in a single copy of a gene on a non-sex chromosome (autosome) is sufficient to cause the disease. Hemophilia does not follow this pattern since it is inherited through the X chromosome and requires a specific set of conditions, particularly affecting males due to the lack of a second X chromosome. D. X-linked dominant This option is incorrect because X-linked dominant disorders are characterized by a mutation in a gene on the X chromosome that can cause the disease in both males and females, though females often have milder symptoms. In X-linked dominant inheritance, affected fathers cannot pass the disease to their sons, but all daughters inherit the condition. Hemophilia does not exhibit this pattern because it is recessive and primarily affects males, with females usually being carriers.",
      "correct_choice_id": 294089,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52821811705131352/52821811705131352.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52821811705131352/52821811705131352.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83142,
      "choices": [
        {
          "id": 294091,
          "text": "Pregnancy"
        },
        {
          "id": 294092,
          "text": "Myeloproliferative disorders"
        },
        {
          "id": 294093,
          "text": "Antiphospholipid antibody syndrome"
        },
        {
          "id": 294094,
          "text": "All the above"
        }
      ],
      "text": "Which of the following can lead onto venous thrombosis ?",
      "unique_key": "Q7337316",
      "question_audio": null,
      "question_video": null,
      "map_id": 34626987,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. Venous thrombosis refers to the formation of blood clots in veins, often resulting from a hypercoagulable state, stasis of blood flow, or vascular injury, as described in Virchow's triad. Each of the given conditions—pregnancy, myeloproliferative disorders, and antiphospholipid antibody syndrome—contributes to one or more of these factors, significantly increasing the risk of venous thrombosis. Pregnancy: Pregnancy is a recognized hypercoagulable state due to increased levels of procoagulant factors (such as fibrinogen and factor VIII), decreased anticoagulant activity, and reduced fibrinolysis. Additionally, the mechanical compression of pelvic veins by the growing uterus can lead to stasis of blood flow, further promoting thrombosis. The risk of venous thrombosis is especially heightened during the postpartum period. Myeloproliferative Disorders: These disorders, such as polycythemia vera or essential thrombocythemia, involve the overproduction of blood cells, leading to increased blood viscosity and a predisposition to thrombosis. In these conditions, both arterial and venous thromboses are common complications. Antiphospholipid Antibody Syndrome (APS): APS is an autoimmune condition characterized by the presence of antiphospholipid antibodies that interfere with coagulation. These antibodies promote thrombosis by enhancing platelet activation, impairing fibrinolysis, and damaging endothelial cells. APS is a major cause of recurrent venous thrombosis, particularly in younger individuals. A. Pregnancy This option is correct because pregnancy significantly increases the risk of venous thrombosis due to the hypercoagulable state and mechanical factors, as explained above. However, pregnancy alone is not the sole cause of venous thrombosis, as other risk factors or conditions can also contribute. B. Myeloproliferative Disorders This option is correct because these disorders cause an increase in blood cell production, leading to hyperviscosity and a prothrombotic state. They play a direct role in predisposing individuals to both arterial and venous thrombotic events. C. Antiphospholipid Antibody Syndrome This option is correct because APS is a well-documented cause of venous thrombosis, particularly in young individuals or those with unexplained recurrent thrombosis. It is an important cause to consider in patients with thrombosis and associated autoimmune features.",
      "correct_choice_id": 294094,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4144251705131364/4144251705131364.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4144251705131364/4144251705131364.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83143,
      "choices": [
        {
          "id": 294095,
          "text": "10%"
        },
        {
          "id": 294096,
          "text": "30%"
        },
        {
          "id": 294097,
          "text": "50%"
        },
        {
          "id": 294098,
          "text": "90%"
        }
      ],
      "text": "The bioavailability of LMWH after subcutaneous administration is :",
      "unique_key": "Q8128137",
      "question_audio": null,
      "question_video": null,
      "map_id": 34980685,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) 90%. Low Molecular Weight Heparins (LMWHs) have a high bioavailability after subcutaneous (SC) administration due to their smaller molecular size and more predictable pharmacokinetics compared to unfractionated heparin. After SC administration, LMWH is efficiently absorbed into the bloodstream, with a bioavailability of approximately 90%. This high bioavailability, along with a longer half-life, makes LMWHs a preferred choice for anticoagulation in many clinical settings, as they allow for once or twice-daily dosing without the need for frequent monitoring. A. 10% This option is incorrect because a bioavailability of 10% is extremely low and not representative of LMWH. Such low bioavailability might occur in poorly absorbed medications or those undergoing extensive first-pass metabolism, which is not the case with LMWH. B. 30% This option is incorrect because LMWH has a far higher bioavailability than 30%. Such a low value might apply to other medications with suboptimal absorption but not to LMWH, which is designed for effective SC administration. C. 50% This option is incorrect because while 50% bioavailability is closer to the realm of possibility, it is still significantly lower than the actual bioavailability of LMWH, which is around 90%. LMWHs are specifically engineered for high bioavailability via SC administration, making this answer unsuitable.",
      "correct_choice_id": 294098,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44544401705131375/44544401705131375.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44544401705131375/44544401705131375.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83144,
      "choices": [
        {
          "id": 294099,
          "text": "Hemophilia A"
        },
        {
          "id": 294100,
          "text": "Hemophilia B"
        },
        {
          "id": 294101,
          "text": "ITP"
        },
        {
          "id": 294102,
          "text": "vWD"
        }
      ],
      "text": "A 21-year-old woman presented with abnormal bleeding after a minor cut while working in kitchen. She was taking aspirin for a headache for 3 days. The skin kept oozing blood for more than 2 days. She gave past medical history of prolonged bleeding after dental extraction. On examination- Skin: bleeding from skin cut, petechiae of lower extremities. Vitals-stable. CBC: Hb 12.2 g/dl,; WBCs 7000/μL; platelets 245,000/μL (normal) PT: 11 seconds (normal) aPTT: 66 seconds (abnormally prolonged) Chemistry and LFTs: normal. What is the likely cause of her bleeding",
      "unique_key": "Q6749862",
      "question_audio": null,
      "question_video": null,
      "map_id": 34599127,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Causes of prolonged aPTT • Deficiency of factor VIII, IX, XI, XII • Acquired inhibitors of these factors • von Willebrand disease (vWD) • Antiphospholipid syndromes. Hemophilia occur in males, ITP will have low platelet count hence will not be cause for patient bleeding.Out of given options best answer is vwD. Clinical pearls Platelet-Related Bleeding presents as Skin–petechiae • Nasal–epistaxis • Gums and gingiva • Vaginal Factor-Related Bleeding presents as Joints–hemarthrosis • Muscles and hematoma When vWF level is decreased, it is not there to bind factor VIII. This elevates the aPTT. Besides endothelial cells and the connective tissue of the vessel wall, vWF is also made by megakaryocytes.",
      "correct_choice_id": 294102,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25621701698818180/25621701698818180.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25621701698818180/25621701698818180.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83145,
      "choices": [
        {
          "id": 294103,
          "text": "Increased production of vWF"
        },
        {
          "id": 294104,
          "text": "Increased expression of vWF receptors"
        },
        {
          "id": 294105,
          "text": "Inhibition of ADAMTS 13"
        },
        {
          "id": 294106,
          "text": "Release of subendothelial stores of vWF and factor VIII"
        }
      ],
      "text": "A 25 year old male diagnosed as a case of type 1 vWD. The vWF antigen level is low. The ristocetin cofactor activity level is markedly impaired. The patient needs her wisdom teeth removed. You are planning to give desmopressin (DDAVP) prior to the procedure. What is the mechanism of DDAVP?",
      "unique_key": "Q3807598",
      "question_audio": null,
      "question_video": null,
      "map_id": 34044996,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Release of subendothelial stores of vWF and factor VIII. Desmopressin (DDAVP) is a synthetic analogue of vasopressin and is used in type 1 von Willebrand disease (vWD) to temporarily increase the levels of von Willebrand factor (vWF) and factor VIII. In type 1 vWD, the deficiency in vWF leads to a bleeding tendency, and DDAVP is effective in increasing the release of vWF and factor VIII from the subendothelial stores (such as in the endothelial cells). This results in transient improvement in platelet adhesion and aggregation at the site of vascular injury, helping to manage bleeding during procedures like wisdom tooth removal. Incorrect Options: A. Increased production of vWF DDAVP does not directly increase the production of vWF. Instead, it acts by promoting the release of vWF from stores in endothelial cells, not by increasing its synthesis. The increase in vWF is temporary and primarily occurs by the release of preformed vWF, which is different from a long-term increase in production. B. Increased expression of vWF receptors DDAVP does not increase the expression of vWF receptors. The primary action of DDAVP in type 1 vWD is the release of stored vWF and factor VIII, not the upregulation of their receptors (e.g., GPIb receptors on platelets). The receptor expression is generally stable, and DDAVP works on enhancing the availability of vWF for platelet binding, rather than altering receptor levels. C. Inhibition of ADAMTS 13 ADAMTS 13 is an enzyme that cleaves large multimers of vWF into smaller forms. While deficiency of ADAMTS 13 is important in Thrombotic Thrombocytopenic Purpura (TTP), DDAVP does not inhibit ADAMTS 13. In type 1 vWD, there is a low level of vWF, and DDAVP works by increasing the release of vWF from endothelial stores, not by altering ADAMTS 13 activity.",
      "correct_choice_id": 294106,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77985111698818193/77985111698818193.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77985111698818193/77985111698818193.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83146,
      "choices": [
        {
          "id": 294107,
          "text": "Aminocaproic acid"
        },
        {
          "id": 294108,
          "text": "Factor VIII replacement"
        },
        {
          "id": 294109,
          "text": "Protamine sulfate"
        },
        {
          "id": 294110,
          "text": "Steroids"
        }
      ],
      "text": "In previous case DDAVP is given and the dental extraction is performed. Bleeding persists and a subsequent dose of DDAVP is ineffective. At this point, what medication should you use?",
      "unique_key": "Q9242751",
      "question_audio": null,
      "question_video": null,
      "map_id": 34101337,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Factor VIII replacement. In the scenario where desmopressin (DDAVP) has been administered, but bleeding persists, and a subsequent dose of DDAVP is ineffective, this indicates that the patient’s von Willebrand factor (vWF) and factor VIII levels have not increased adequately to control bleeding. This is particularly common in type 1 von Willebrand disease (vWD), where there is insufficient vWF to stabilize factor VIII in circulation. Since DDAVP primarily works by releasing stored vWF and factor VIII from the endothelial cells, but if the release is inadequate or if the patient has a more severe form of vWD, factor VIII replacement is the most appropriate next step. This will provide the necessary factor VIII directly to manage the bleeding, as factor VIII is crucial for clot formation and stabilization of the fibrin clot. Incorrect Options: A. Aminocaproic acid Aminocaproic acid is an antifibrinolytic agent that inhibits the breakdown of fibrin clots by preventing plasminogen activation. While it can be useful in cases of bleeding where fibrinolysis is excessive, it is not the appropriate treatment in this case. The patient’s bleeding is due to a deficiency in factor VIII and vWF, not excessive fibrinolysis, so aminoacaproic acid would not address the underlying problem. C. Protamine sulfate Protamine sulfate is used to reverse the effects of heparin, an anticoagulant. It is not relevant to this case, as the patient is not on heparin therapy, and the bleeding is not related to anticoagulation but to a deficiency in clotting factors (vWF and factor VIII). D. Steroids Steroids are typically used to treat autoimmune or inflammatory conditions, such as autoimmune hemolytic anemia or immune-mediated platelet destruction. In this case, the cause of bleeding is related to a deficiency in clotting factors due to von Willebrand disease, and steroids would not correct the underlying issue of factor VIII deficiency. Steroids are not effective in improving factor VIII or vWF levels.",
      "correct_choice_id": 294108,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57800161698818204/57800161698818204.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57800161698818204/57800161698818204.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83147,
      "choices": [
        {
          "id": 294111,
          "text": "Factor VIII deficiency"
        },
        {
          "id": 294112,
          "text": "Factor IX deficiency"
        },
        {
          "id": 294113,
          "text": "Factor XI deficiency"
        },
        {
          "id": 294114,
          "text": "Factor XI inhibitor"
        }
      ],
      "text": "A 54-year-old woman comes with an elevated aPTT that her surgeon found prior to a planned lumpectomy for breast cancer. Needle biopsy showed infiltrating ductal carcinoma. Bleeding was not excessive at the time of the biopsy. Laboratory Test Results: CBC and LFTs: normal ,PT and INR: normal, aPTT: prolonged to 60 seconds. The mixing study shows a normalization of aPTT. Which coagulation factor abnormality is most likely in the patient",
      "unique_key": "Q1830246",
      "question_audio": null,
      "question_video": null,
      "map_id": 34521310,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) The Causes of prolonged aPTT are • Deficiency of factor VIII, IX, XI, XII • Acquired inhibitors of these factors • von Willebrand disease (vWD) • Antiphospholipid syndromes. Mixing studies will not correct aPTT if inhibitors of coagulation factors are present. The patient’s gender and age eliminate the possibility of hemophilia (factor VIII and IX deficiency). Hence out of options given factor XI deficiency is most likely cause here. Give FFP before operative procedures to patients with factor XI deficiency. Clinical pearls- Factor XII deficiency is never associated with bleeding and never needs treatment. Factor XIII deficiency does cause bleeding, but it is not in the clotting cascade, so aPTT is normal. Factor XIII is “clot stabilizing factor” and may make fibrin permanently resistant to the effects of plasmin. FFP has all clotting factors except: • Factor VIII • vWF",
      "correct_choice_id": 294113,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25601731698818215/25601731698818215.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25601731698818215/25601731698818215.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}